The purpose of this study is to observe the efficacy and safety of liposomal irinotecan combined with apatinib in the treatment of extensive stage small cell lung cancer progressed from first-line regimen.
Phase:
PHASE2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University